Goodwin Procter advised Repligen Corporation, while Paul Hastings advised 908 Devices Inc. on the transaction. Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing...
You must be a Standard 1 Year member to access this content.
Strengthening the firm’s global M&A capabilities and emerging companies/venture capital practice, and further expanding its presence in Boston, Paul Hastings LLP announced that Ian Engstrand has...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis represented Vista Equity Partners and TCV in the transaction, and Goodwin Procter represented Nasuni. Nasuni announced a majority investment led by Vista Equity...
You must be a Standard 1 Year member to access this content.
